Inhaled Drug Developer Risproly Closes ￥200 million Series B Financing Round

(VCBeat) Feb. 1, 2021 -- Risproly, an innovative pharmaceutical company focused on the development of inhaled drug delivery technology, announced today closing a Series B financing of nearly ￥200 million. This round was led by SCGC, with participation from YuanBio Venture Capital, Cowin Capital, Qianhai FOF, Tianfeng Capital, EFung Capital, and others. The fresh round of funding will be used to expand the company's existing GMP compliant production line and develop the pipeline of high-end inhalation preparations and inhaled drugs.

Prior to this, Risproly has raised tens of millions in Series A financing round from Huaige Capital, Yanghe Investment, Gree Financial Investment, Kindly Group, and Zhuhai Science and Technology Venture Capital in 2019.

Founded in 2018, Risproly is committed to the R&D and production of leading inhaled drugs and related devices. Its products under development cover indications of the respiratory system, including asthma, chronic obstructive pulmonary disease (COPD), central nervous system disease(CNS), and other treatments of high demand. 2 to 3 drugs of Risproly in development are going to enter clinical trials in 2 years.

Before the establishment of Risproly, the founder Dr. Chen Yongqi worked at Vectura, a world leader in the development of inhaled drug delivery technology, and served as chief scientist of inhalation products with more than 20 years of experience. Dr. Chen has led and participated in the successful development of 13 major aerosols and powder aerosols among the 17 inhaled drugs on the global market.

SCGC is a limited venture capital company established by Shenzhen Government in 1999. SCGC has a registered capital of 5.42 billion yuan. It primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in the start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumer goods, modern service, etc.

Founded at BioBay of Suzhou Industrial Park and portfolio spreading China and globally, YuanBio Venture Capital focuses on early and growth-stage life science and healthcare investment. Its total AUM is close to 5 billion RMB. The portfolio includes over 70 companies across BioPharma, MedTech, IVD, and Health Services sectors. YuanBio Venture Capital aims to be one of the most successful healthcare venture capital firms in China.